



Jan Frehner

Administration

Medizinische Onkologie und Hämatologie · Dept. I

Contact

Jan Frehner
Rorschacherstrasse 95
9007 St. Gallen
Switzerland

T +41 71 494 6872
Jan.Frehner@kssg.ch

Units

Medizinische Onkologie und Hämatologie

Profile Function

Administration

Publications (0)

No results found.

Projects (23)

Combination of Abemaciclib and endocrine therapy in hormone receptor positive HER2 negative locally advanced or metastatic breast cancer with focus on digital side effect management. The MINERVA Trial – A phase IV Trial

Clinical Studies - Feb 29, 2024 - Dec 31, 2028

Ongoing

Retrospective and prospective registry of patients with metastatic NSCLC harboring typical and atypical EGFR mutations

Clinical Studies - Jul 3, 2023 - Dec 31, 2030

Ongoing

A Phase 1/2 Study of BMS-986408 Alone and in Combination with Nivolumab or with Nivolumab and Ipilimumab in Participants with Advanced Solid Tumors

Clinical Studies - Jun 21, 2023 - Dec 31, 2030

Ongoing

A PHASE IB/II RANDOMIZED, OPEN LABEL DRUG REPURPOSING TRIAL OF GLUTAMATE SIGNALING INHIBITORS IN COMBINATION WITH CHEMORADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GLUGLIO)

Clinical Studies - May 10, 2023 - Dec 31, 2030

Ongoing

A Phase 1 Study of ANV419 as Monotherapy, and ANV419 in Combination With Daratumumab or With Lenalidomide Plus Low-Dose Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma

Clinical Studies - Jan 23, 2023 - Dec 31, 2025

Aborted

A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE™ FL-1)

Clinical Studies - Dec 7, 2022 - Dec 31, 2029

Ongoing

An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care (SOC) anti-cancer therapy for the second line treatment of metastatic colorectal cancer (mCRC)

Clinical Studies - Nov 16, 2022 - Mar 31, 2025

Ongoing

A Phase 1 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Tinostamustine, a Novel Alkylating and Deacetylase Inhibiting Molecule, as Adjuvant Treatment in Patients with Newly Diagnosed Unmethylated MGMT-promoter Glioblastoma

Clinical Studies - Oct 10, 2022 - Jun 30, 2024

Ongoing

Phase 3 Study of Teclistamab in Combination with Lenalidomide versus Lenalidomide Alone in Participants with Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Clinical Studies - Aug 23, 2022 - Aug 24, 2030

Ongoing

A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING IBERDOMIDE, DARATUMUMAB AND DEXAMETHASONE (IberDd) VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (DVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) (EXCALIBER-RRMM)

Clinical Studies - Aug 2, 2022 - Aug 5, 2030

Ongoing

Muscle-invasive bladder cancer (MIBC) and perioperative treatment

Clinical Studies - May 13, 2022 - May 13, 2032

Ongoing

INCMOR0208-301: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TAFASITAMAB PLUS LENALIDOMIDE IN ADDITION TO RITUXIMAB VERSUS LENALIDOMIDE IN ADDITION TO RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) GRADE 1-3A OR R/R MARGINA

Clinical Studies - Apr 20, 2022 - Dec 31, 2025

Ongoing

CAR T- Cell EBMT Registry data processing framework

Clinical Studies - Jul 30, 2021 - Dec 31, 2026

Ongoing

Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Clinical Studies - Jul 30, 2021 - Dec 31, 2026

Ongoing

SAKK 67/20 Open-label single-stage phase 1B study of the new micellar docetaxel compound Docecal in patients with advanced castration-resistant prostate cancer

Clinical Studies - May 28, 2021 - Dec 31, 2024

Completed

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination with Acalabrutinib in Subjects with Relapsed/Refractory Diffuse Large B-cell Lymphoma or Relapsed/Refractory Chronic Lymphocytic Leukemia

Clinical Studies - Apr 22, 2021 - May 20, 2030

Ongoing

Swiss Soliris® and Ultomiris® Reimbursement Registry SSURR: An observational registry for capturing data of patients suffering from paroxysmal nocturnal hemoglobinuria (PNH) who are treated with Soliris® (eculizumab) or Ultomiris® (ravulizumab)

Clinical Studies - Jan 1, 2021 - Dec 31, 2030

Ongoing

Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD - L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III (N2) non -small cell lung cancer (NSCLC)

Clinical Studies - Apr 29, 2020 - Aug 24, 2030

Ongoing

EMCL-Registry of the European Mantle Cell Lymphoma study group

Clinical Studies - Dec 20, 2019 - Dec 31, 2030

Ongoing

Tailored AXILLary Surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS)

Clinical Studies - Jul 30, 2018 - Dec 12, 2030

Ongoing

Multicentre Oberservational Study of MDS Patients in Switzerland- Swiss MDS Registry

Clinical Studies - May 17, 2018 - Aug 14, 2030

Ongoing

Swiss Austrian German Testicular Cancer Cohort Study – SAG TCCS

Clinical Studies - Oct 3, 2013 - Dec 31, 2026

Ongoing

A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)

Clinical Studies - Mar 26, 23 - Dec 21, 2030

Ongoing